ADC THERAPEUTICS SARL has a total of 28 patent applications. It decreased the IP activity by 60.0%. Its first patent ever was published in 2013. It filed its patents most often in United Kingdom, Brazil and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are BERLIN CHEMIE AG, TECHNICLONE INC and NEURALAB LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 9 | |
#2 | Brazil | 5 | |
#3 | Canada | 5 | |
#4 | Republic of Korea | 5 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | Australia | 1 | |
#7 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology | |
#4 | Organic fine chemistry | |
#5 | Measurement |
# | Name | Total Patents |
---|---|---|
#1 | Van Berkel Patricius Hendrikus Cornelis | 14 |
#2 | Howard Philip Wilson | 14 |
#3 | Patricius Hendrikus Cornelis Van Berkel | 5 |
#4 | Philip Wilson Howard | 5 |
Publication | Filing date | Title |
---|---|---|
GB201907010D0 | Pyrrolobenzodiazepine phototherapy | |
GB201820725D0 | Pyrrolobenzodiazepine resistance | |
GB201805660D0 | Combination Therapy | |
GB201709439D0 | Dosage regime | |
GB201709441D0 | Dosage regime | |
GB201709444D0 | Dosage regime | |
GB201709440D0 | Dosage regime | |
GB201706260D0 | Combination therapy | |
GB201507827D0 | Diagnostic test | |
WO2014057118A1 | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |